Compare Alcon AG (ALC) vs Chart Industries Inc (GTLS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Chart Industries Inc — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while Chart Industries Inc trades at $209.09 (market cap $10.02B). The key difference: Alcon AG is far larger — about 3.3× Chart Industries Inc's market cap, and Alcon AG pays a 0.54% dividend while Chart Industries Inc pays none. Which is the better fit depends on your goals.
| ALC | GTLS | |
|---|---|---|
Market Cap | $32.69B | $10.02B |
Sector | Health | Technology |
52-Week High | $92.22 | $209.29 |
52-Week Low | $62.02 | $164.90 |
Enterprise Value | $36.28B | $13.54B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
GTLS trades at $208.73 with minimal daily movement, showing technical bullish signals from moving averages while oscillators remain neutral. The company reported $4.26B revenue for 2025 but has missed earnings expectations for three consecutive quarters, with negative profit margins and elevated valuation ratios. Recent news highlights Baker Hughes' pending $13.6B acquisition and new supply agreements supporting future growth.
Investment outlook remains mixed with strong analyst buy consensus (54%) offset by recent earnings underperformance. Key opportunities include acquisition premium potential and operational scale, while risks center on profitability challenges and integration execution. The stock's valuation appears stretched given current negative returns on equity and assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Chart Industries Inc
Chart Industries is a leading manufacturer of highly engineered cryogenic equipment. Its products are used throughout the liquid gas supply chain, including clean energy applications like hydrogen and LNG.
Read more on GTLS →
